GOLGA6L4 Activators
GOLGA6L4 Activators are a set of chemical compounds that serve to indirectly enhance the functional activity of GOLGA6L4 through a variety of mechanisms focusing on the Golgi apparatus, which is central to protein processing and trafficking within the cell. Compounds such as Forskolin and Ionomycin act by increasing intracellular levels of cAMP and calcium, respectively, which leads to the activation of kinases such as PKA that could phosphorylate proteins relevant to Golgi structure and function, potentially enhancing the role of GOLGA6L4 within this organelle. Similarly, Phorbol 12-myristate 13-acetate (PMA) and Ceramide exert their effects by activating PKC and modifying the lipid composition of the Golgi membrane, which can have a downstream effect on GOLGA6L4's involvement inmaintaining the Golgi's structural integrity and its associated trafficking pathways. Okadaic Acid, through the inhibition of protein phosphatases, and Epigallocatechin gallate (EGCG), by inhibiting specific kinases, both lead to increased phosphorylation within the cell that may necessitate an upregulation of GOLGA6L4 activity to sustain Golgi function.
On the other hand, compounds like Brefeldin A, Nocodazole, and Golgicide A disrupt the Golgi apparatus by different mechanisms, such as inhibiting ARF, destabilizing microtubules, and inhibiting GBF1, respectively. These disruptions may indirectly necessitate an enhancement of GOLGA6L4 activity as part of the cellular response to restore normal Golgi function. Additionally, Monensin and Nigericin, both ionophores, alter ion gradients and pH within the Golgi, which could indirectly lead to increased GOLGA6L4 activity in an attempt to compensate for the disturbed homeostasis. Furthermore, Lipopolysaccharide (LPS) activates TLR4 signaling, with downstream effects that could include the enhancement of GOLGA6L4's function as part of the cellular inflammatory response, indicating a broad spectrum of cellular processes that can converge to modulate GOLGA6L4 activity in the context of Golgi dynamics and function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to an increase in cAMP levels, which subsequently activates PKA. Activation of PKA can enhance the phosphorylation of proteins associated with the Golgi apparatus, thus potentially increasing the functional activity of GOLGA6L4 by promoting its involvement in Golgi structure maintenance and protein trafficking. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). PKC activation can influence Golgi function and structure. Hence, PMA could enhance the activity of GOLGA6L4 by facilitating protein processing and trafficking within the Golgi apparatus. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid inhibits protein phosphatases PP1 and PP2A, leading to an increase in the phosphorylation state of cellular proteins. Enhanced phosphorylation could influence Golgi dynamics and thereby indirectly increase the activity of GOLGA6L4 in the Golgi apparatus. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts Golgi structure by inhibiting ADP-ribosylation factor (ARF), which is essential for maintaining Golgi integrity. By disturbing normal Golgi function, Brefeldin A could indirectly lead to compensatory mechanisms that increase GOLGA6L4 activity to restore Golgi structure. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization. Microtubules are crucial for Golgi organization and vesicular traffic. The disruption caused by Nocodazole could indirectly enhance GOLGA6L4 activity as the cell attempts to maintain Golgi apparatus function. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that alters ion gradients across Golgi membranes, affecting intracellular transport and Golgi function. This alteration may indirectly enhance the function of GOLGA6L4 through compensatory mechanisms aimed at maintaining protein trafficking. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A specifically inhibits Golgi BFA resistance factor 1 (GBF1), a GTPase involved in Golgi trafficking. Inhibition of GBF1 can lead to changes in Golgi dynamics, potentially enhancing the role of GOLGA6L4 in response to altered Golgi function. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, potentially affecting Golgi function. Elevated calcium may enhance GOLGA6L4 function as it could influence Golgi-associated protein processing and trafficking. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG has multiple cellular effects, including inhibiting specific kinases. By altering kinase activity, EGCG might impact Golgi function, leading to a scenario where GOLGA6L4 activity is enhanced as a compensatory mechanism for maintaining Golgi integrity. | ||||||